Ove informacije služe isključivo u edukativne svrhe. Ne predstavljaju medicinski savjet. Uvijek se posavjetujte s kvalificiranim zdravstvenim stručnjakom.
Opis, Doziranje, Nuspojave, Kontraindikacije. Data from EMA, URPL, openFDA and other regulatory sources.
| Semaglutide | Liraglutide | |
|---|---|---|
| Djelatne tvari | Semaglutide | LIRAGLUTIDE |
| ATK oznaka | A10BJ06 | A10BJ02 |
| Oblik | Roztwór do wstrzykiwań we wstrzykiwaczu | SOLUTION |
| Doziranje | 0,5 mg | 18MG/3ML (6MG/ML) |
| Način primjene | — | SUBCUTANEOUS |
| Proizvođač | Novo Nordisk A/S | FRESENIUS KABI USA LLC |
Semaglutide (INN: Semaglutide, ATC A10BJ06) and Liraglutide (INN: LIRAGLUTIDE, ATC A10BJ02) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
Ove informacije služe isključivo u edukativne svrhe. Ne predstavljaju medicinski savjet. Uvijek se posavjetujte s kvalificiranim zdravstvenim stručnjakom.